Uncategorized
Novaliq announces positive phase 1 results for dry eye drops
Novaliq has announced positive phase 1 results for its dry eye agent, CyclASol, according to a press release.Eighteen healthy patients were included in the phase 1, double-blind, randomized, placebo-controlled crossover study that investigated the safety, local tolerability and systemic exposure of CyclASol (0.05% cyclosporin solution, Novaliq) eye drops and vehicle after single and multiple ocular doses.